Orchid was founded with the core mission of significantly reducing the incidence rates of various diseases in future generations. The company focuses on early-stage risk detection and prevention, offering couples the ability to enhance their children's health span—years of life free from disease. Orchid's technology targets a wide range of conditions, including intellectual disabilities, autism spectrum disorders, epilepsy, Alzheimer's disease, bipolar disorder, schizophrenia, coronary artery disease, various cancers, and both Type I and Type II diabetes.

Notable affiliated individuals and investors include leading experts and venture capitalists in the biotech and healthcare sectors. Orchid has achieved significant milestones in advancing genetic screening and risk assessment technologies. Their impact is evident in the growing number of families who benefit from early disease detection and prevention, ultimately contributing to a healthier next generation.